The law firm Smart & Biggar recently published an overview of some key developments for biosimilars in Canada, including approvals, pending submissions and litigation. Health Canada has approved 36 biosimilars to date and has 16 biosimilar submissions under review.
Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
For Alberta and Green Shield Canada savings are beginning to add up from switching initiatives for multiple reference biologics, reports the American Journal of Managed Care (AJMC).
CBC News report on the announcement of the province’s biosimilars initiative.
Following the lead of British Columbia and Alberta, New Brunswick hopes to save on biologics, reports The Center for Biosimilars.
The provincial government is improving the sustainability of its public drug plans by expanding the use of biosimilars. In consultation with their physicians, about 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from an originator biologic to the biosimilar version.
Coverage by The Center for Biosimilars of the adalimumab phase of the BC’s biosimilars program.